Ideaya Biosciences (IDYA) announced first-patient-in for a Phase 1 clinical trial combination study to evaluate IDE849, a delta-like ligand 3-targeting Topo-I-payload antibody drug conjugate program, and IDE161, a poly glycohydrolase inhibitor. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer, neuroendocrine tumors, neuroendocrine carcinomas and melanoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release
- Ideaya Biosciences falls -6.0%
- IDEAYA Biosciences: Operational Trial Delay but High Conviction Buy Ahead of Key Darovasertib Readout
- IDEAYA Biosciences: Expanding Precision Oncology Platform and Refocused MTAP Strategy Support Buy Rating
- Ideaya Biosciences enrolls first patient in IDE892 trial